Get access to our best features

'Skinny labels' on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period

Summary by Ground News
The provision is known as skinny labeling, which refers to a move by a company that seeks regulatory approval to market a generic or biosimilar medicine. By doing so, the company seeks to avoid lawsuits in which the brand-name manufacturer could claim patent infringement. Medicare saved $1.5 billion from 2015 to 2020, or nearly 5% of the $30.2 billion spent by the health care program.
Published 2 months ago

News Articles

More Filters
All
Left
Center
Right

'Skinny labels' on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period

Skinny labeling on biosimilar drugs saved Medicare $1.5 billion between 2015 and 2020 on just five medicines during that period.

2 months ago
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

100% of the sources are Center
STAT
C 100%
See less detail